Stroke. 1997 Nov;28(11):2109-18. doi: 10.1161/01.str.28.11.2109.
We sought to identify variables associated with intracerebral hemorrhage in patients with acute ischemic stroke who receive tissue plasminogen activator (t-PA).
We performed subgroup analyses of data from a randomized, double-blind, placebo-controlled trial of intravenous t-PA administered to stroke patients within 3 hours of onset. Using multivariable regression modeling procedures, we assessed the relationship of baseline and after-treatment variables with symptomatic and asymptomatic intracerebral hemorrhage during the first 36 hours after treatment.
Overall, t-PA-treated patients had an increase in the absolute risk of symptomatic intracerebral hemorrhage of 6% and a decrease in the absolute risk of 3-month mortality of 4% compared with placebo-treated patients. The only variables independently associated with an increased risk of symptomatic intracerebral hemorrhage in the final multivariable logistic regression model for the 312 t-PA-treated patients were the severity of neurological deficit as measured by the National Institutes of Health Stroke Scale score (five categories; odds ratio [OR], 1.8; 95% confidence interval [CI], 1.2 to 2.9) and brain edema (defined as acute hypodensity) or mass effect by CT before treatment (OR, 7.8; 95% CI, 2.2 to 27.1). This final model correctly predicted those t-PA-treated patients who would or would not have a symptomatic hemorrhage with only 57% efficiency. In the subgroup of patients with a severe neurological deficit, t-PA-treated patients were more likely than placebo-treated patients to have a favorable 3-month outcome (adjusted OR based on multiple outcomes, 4.3; 95% CI, 1.6 to 11.9). These results were similar for the subgroup with edema or mass effect by CT (adjusted OR, 3.4; 95% CI, 0.6 to 20.7). The likelihood of severe disability or death was similar for t-PA- and placebo-treated patients with these two baseline characteristics.
Despite a higher rate of intracerebral hemorrhage, patients with severe strokes or edema or mass effect on the baseline-CT are reasonable candidates for t-PA, if it is administered within 3 hours of onset.
我们试图确定接受组织型纤溶酶原激活剂(t-PA)治疗的急性缺血性卒中患者发生脑出血的相关变量。
我们对一项在卒中发病3小时内静脉给予t-PA的随机、双盲、安慰剂对照试验的数据进行了亚组分析。使用多变量回归建模程序,我们评估了基线及治疗后变量与治疗后36小时内有症状和无症状脑出血之间的关系。
总体而言,与安慰剂治疗的患者相比,接受t-PA治疗的患者有症状脑出血的绝对风险增加了6%,3个月死亡率的绝对风险降低了4%。在针对312例接受t-PA治疗患者的最终多变量逻辑回归模型中,唯一与有症状脑出血风险增加独立相关的变量是通过美国国立卫生研究院卒中量表评分衡量的神经功能缺损严重程度(分为五类;比值比[OR],1.8;95%置信区间[CI],1.2至2.9)以及治疗前CT显示的脑水肿(定义为急性低密度)或占位效应(OR,7.8;95%CI,2.2至27.1)。该最终模型正确预测接受t-PA治疗的患者是否会发生有症状出血的效率仅为57%。在神经功能缺损严重的患者亚组中,接受t-PA治疗的患者比接受安慰剂治疗的患者更有可能在3个月时获得良好结局(基于多种结局调整后的OR,4.3;95%CI,1.6至11.9)。对于CT显示有水肿或占位效应的亚组,结果相似(调整后的OR,3.4;95%CI,0.6至20.7)。有这两种基线特征的接受t-PA治疗和接受安慰剂治疗的患者发生严重残疾或死亡的可能性相似。
尽管脑出血发生率较高,但对于基线CT显示有严重卒中、水肿或占位效应的患者,如果在发病3小时内给予t-PA,仍是合理的治疗对象。